甲状腺髓样癌第八版TNM分期预后分组的临床验证
该研究回顾性分析了1995至2015年间在韩国一家三级医院治疗的182例甲状腺髓样癌(MTC)患者,比较第八版AJCC/UICC TNM分期(TNM-8)与基于递归分割分析提出的预后分组(TNM-RPA)的预后判别能力。结果显示TNM-8相对第七版(TNM-7)预测性能无明显改善,而TNM-RPA在癌症特异性生存方面表现更优。
要点
- TNM-8相对TNM-7仅1.1%患者降期,预测性能基本未变。
- TNM-RPA较TNM-8使57.14%患者降期,判别能力更优。
- TNM-8的10年AUC为0.681、PVE为8.9%、C-index为0.747。
核心结论
- TNM-8在MTC患者中的预测性能较TNM-7未见改善。
- TNM-RPA提出的分组变化在统计学上有效,可能提供更可重复、更好估计个体癌症特异性生存的系统。
研究设计与样本
- 回顾性分析1995至2015年韩国一家三级医院治疗的182例MTC患者。
- 按TNM-8与TNM-RPA进行生存分析,并以AUC、PVE和C-index评价预测性能。
主要发现
- TNM-8下仅2例(1.1%)患者较TNM-7降期。
- TNM-7的10年AUC为0.679、PVE为8.7%、C-index为0.744;TNM-8分别为0.681、8.9%、0.747。
- TNM-RPA下104例(57.14%)患者较TNM-8降期。
- TNM-RPA对癌症特异性生存的10年AUC为0.750、PVE为20.9%、C-index为0.881。
临床怎么用
- 对MTC患者可关注TNM-RPA分组以更好估计个体癌症特异性生存。
- TNM-8较TNM-7分期改动对MTC预后判别影响有限。
局限性
- 研究为单中心韩国医院回顾性分析,样本量182例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite advances in thyroid cancer staging systems, considerable controversy about the current staging system for medullary thyroid carcinoma (MTC) continues. OBJECTIVE: We aimed to evaluate the prognostic performance of the current eighth edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control TNM staging system (TNM-8) and the alternative proposed prognostic stage groups based on recursive partitioning analysis (TNM-RPA). DESIGN, SETTING, AND PATIENTS: We retrospectively analyzed 182 patients with MTC treated at a single tertiary Korean hospital between 1995 and 2015. INTERVENTIONS AND MAIN OUTCOME MEASURES: Survival analysis was conducted according to TNM-8 and TNM-RPA. The area under the receiver-operating characteristic curve (AUC), the proportion of variation explained (PVE), and the Harrell concordance index (C-index) were used to evaluate predictive performance. RESULTS: Under TNM-8, only two (1.1%) patients were downstaged compared with the seventh edition of the AJCC TNM staging system (TNM-7). The AUC at 10 years, PVE, and C-index were 0.679, 8.7%, and 0.744 for TNM-7 and 0.681, 8.9%, and 0.747 for TNM-8, respectively. Under TNM-RPA, 104 (57.14%) patients were downstaged compared with TNM-8. TNM-RPA had better prognostic performance with respect to cancer-specific survival (AUC at 10 years, 0.750; PVE, 20.9%; C-index, 0.881). CONCLUSIONS: The predictive performance of the revised TNM-8 in patients with MTC has not changed despite its modification from TNM-7. The proposed changes in TNM-RPA were statistically valid and may present a more reproducible system that better estimates cancer-specific survival of individual patients.
引用
- Park SY, Cho YY, Kim HI, et al. Clinical Validation of the Prognostic Stage Groups of the Eighth-Edition TNM Staging for Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018. PMID: 30137493. doi:10.1210/jc.2018-01386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。